07:00 , Jun 21, 2010 |  BC Week In Review  |  Company News

Affomix, University of Montreal Pharmacogenomics Centre, Montreal Heart Institute deal

The parties will discover and produce biomarkers for use in cardiovascular diagnostics. Affomix will contribute its reagents for proteomic profiling of specific cardiovascular targets. Further details were not disclosed. Affomix Corp., Branford, Conn.   University of...
08:00 , Jan 25, 2010 |  BC Week In Review  |  Company News

Affomix, City of Hope National Medical Center deal

Affomix will use its Y2Hexpress and Phage ESCape technologies to develop antibodies for City of Hope. The hospital will use the antibodies with next-generation sequencers to develop proteomic profiles of cancers, including renal and prostate,...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Company News

Affomix, KalGene deal

Affomix will use its Y2HExpress technology to generate antibodies against undisclosed targets from Kalgene for potential diagnostic and therapeutic use in breast cancer. Affomix will receive an upfront payment and is eligible for milestones. Further...
07:00 , May 25, 2009 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Affomix Corp. New Haven, Conn. Technology: Y2HExpress and Phage ESCape automated antibody screening technologies Disease focus: N/A Clinical status: N/A Founded: January 2008 by Michael Sherman, Michael Weiner, Michael Snyder and Sherman Weissman University collaborators: Yale University Corporate partners: Undisclosed Number of employees:...
07:00 , May 25, 2009 |  BioCentury  |  Emerging Company Profile

Affomix: Whole proteome arrays

Antibody arrays are a more accurate tool for measuring protein levels in biological samples than commonly used mRNA-based methods. But the cost and time needed to generate antibodies has limited the space that can be...